CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. ANTIBODY...Antibody Library License Agreement • March 4th, 2021 • Kadmon Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This ANTIBODY LIBRARY LICENSE AGREEM ENT ("Agreement"), effective as of July 22, 2011 (the "Effective Date"), is between DYAX CORP., a Delaware corporation, with offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and KADMON PHARMACEUTICALS LLC, a Delaware limited liability company with its principal place of business at Alexandria Center for Life Sciences, 450 East 29th Street, 5th Floor, New York, New York 10016 ("Licensee").
FIRST AMENDMENT TO THE ANTIBODY LIBRARY LICENSE AGREEMENTAntibody Library License Agreement • March 4th, 2021 • Kadmon Holdings, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO UCENSE AGREEMENT (this "First Amendment"), dated effective as of July 22, 2015 (the "Amendment Date"), is entered into between DYAX CORP., a Delaware, United States corporation, with offices at 55 Network Drive, Burlington Massachusetts 01803, U.S.A. ("Dyax"), and KADMON PHARMACEUTICALS LLC1 a Delaware limited liability company with its principal place of business at Alexandria Center for Life Sciences, 450 East 29th Street, 5th Floor, New York, New York 10016 (""). This First Amendment amends that certain Antibody Library License Agreement (the "Original Agreement"), dated effective as July 22, 2011, by and between Dyax and Kadmon. All capitalized terms not otherwise defined in this First Amendment shall be as defined in the Original Agreement.
